(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 4.24% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Phibro Animal Health's revenue in 2026 is $1,518,093,000.On average, 7 Wall Street analysts forecast PAHC's revenue for 2027 to be $65,246,776,021, with the lowest PAHC revenue forecast at $62,526,468,620, and the highest PAHC revenue forecast at $67,317,457,774. On average, 7 Wall Street analysts forecast PAHC's revenue for 2028 to be $67,561,067,392, with the lowest PAHC revenue forecast at $64,637,751,976, and the highest PAHC revenue forecast at $69,875,358,763.
In 2029, PAHC is forecast to generate $69,794,155,557 in revenue, with the lowest revenue forecast at $66,789,636,935 and the highest revenue forecast at $72,433,259,752.